We are live on ! Find out more
VYNT

Vyant Bio, Inc. Common Stock
VYNT

Delisted

VYNT was delisted on the 12th of May, 2023.

Back to rankings

29 hedge funds and large institutions have $8.41M invested in Vyant Bio, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 8 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

700% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 1

275% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 4

185% more capital invested

Capital invested by funds: $2.96M → $8.41M (+$5.46M)

61% more funds holding

Funds holding: 18 → 29 (+11)

Holders
29
Holders Change
+11
Holders Change %
+61.11%
% of All Funds
0.5%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
8
Reduced
1
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$2.81M
2
BF
Blankinship & Foster
California
+$765K
3
FWM
Frontier Wealth Management
Missouri
+$755K
4
Cerity Partners
Cerity Partners
New York
+$446K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$441K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$839K
2
VF
Virtu Financial
New York
-$69.7K
3
QC
QCM Cayman
Texas
-$50K
4
Citigroup
Citigroup
New York
-$46K
Name Holding Trade Value Shares
Change 		Change in
Stake
Wells Fargo
26
Wells Fargo
California
$1K +$429 +23 +153%
Royal Bank of Canada
27
Royal Bank of Canada
Ontario, Canada
$1K +$932 +50 New
Renaissance Technologies
28
Renaissance Technologies
New York
– -$839K -36,185 Closed
QC
29
QCM Cayman
Texas
– -$50K -2,157 Closed
Citigroup
30
Citigroup
New York
– -$46K -2,000 Closed
Bank of America
31
Bank of America
North Carolina
– +$37 +2 New
1
2

VYNT Hedge Fund Activity: Q2 2021 in Review

29 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio, Inc. Common Stock (VYNT) for Q2 2021, worth a combined $8.41M — up 185% from $2.96M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new VYNT positions and 4 closed out — a net gain of 11 holders — while 8 added to existing stakes and 1 trimmed.

The largest buyer was Vanguard Group, adding an estimated $2.81M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $839K sold.

  • 29 institutional investors held Vyant Bio, Inc. Common Stock (VYNT) as of Q2 2021, up from 18 in Q1 2021.
  • Funds reported $8.41M of Vyant Bio, Inc. Common Stock stock for Q2 2021, up 185% quarter-over-quarter.
  • 15 funds opened new Vyant Bio, Inc. Common Stock positions in Q2 2021 and 4 closed out, a net change of +11 holders.
  • The largest Vyant Bio, Inc. Common Stock buyer in Q2 2021 was Vanguard Group, an estimated $2.81M added.
  • The largest Vyant Bio, Inc. Common Stock seller in Q2 2021 was Renaissance Technologies, an estimated $839K sold.

Based on aggregated 13F filings for Q2 2021.